Nov 23, 2015

Swiss Technology Award for scPharmaceuticals’ Strategic Partner Sensile Medical


Sensile Medical wins as Innovation Leader for micropump at core of sc2Wear Patch Pump–

LEXINGTON, MA. November 23, 2015– scPharmaceuticals, Inc. today announced that its strategic partner, Sensile Medical, was awarded the prestigious Swiss Technology Award in the category “Innovation Leader.” The prize is the most important distinction for innovation and technology transfer in Switzerland. The Swiss Innovation Forum’s jury selected Sensile for its SenseCore technology, a high-precision micropump technology. The award recognizes outstanding technology-based innovations and developments from start-ups, universities and technical institutions as well as established businesses.

scPharmaceuticals holds an exclusive world-wide license from Sensile Medical to the SenseCore technology to develop and commercialize products for subcutaneous administration of certain classes of pharmaceuticals. The SenseCore technology is central to the scPharmaceuticals innovative sc2Wear Patch Pump which allows for convenient subcutaneous administration of medications that now require intravenous infusions or intramuscular injections. Intravenous infusions are considered invasive medical procedures that customarily may only be performed by certified medical professionals, such as nurses, physicians and EMTs.

The sc2Wear Patch Pump is designed to enable convenient and comfortable controlled subcutaneous administration of injectable pharmaceuticals without the resources and costs of intravenous or intramuscular administration. scPharmaceuticals anticipates submitting two 505(b)(2) NDA product filings to the FDA in 2016. The first product is the sc2Wear Furosemide Combination Product for treatment of fluid overload (edema) associated with heart failure. The second product is the sc2Wear Ceftriaxone Combination Product, which is scPharmaceuticals’ first antibiotic pipeline product. Ceftriaxone is a widely-used antibiotic for the treatment of infections due to susceptible pathogens. The sc2Wear Ceftriaxone Patch Pump is intended to reduce risks and costs associated with antibiotic courses that require daily intravenous administration by means of a peripherally inserted central catheter (PICC). A PICC, also called a PIC line, is the standard method to administer ceftriaxone and other injectable antibiotics when a course of longer duration, typically seven days or more, is indicated.

For each application, the sc2Wear Pump will incorporate a unique pre-programmed delivery profile tailored to the application.

In 2012 we selected the SenseCore for application in our patch pump based on a thorough review of relevant core technologies from around the world”, said Pieter Muntendam, MD, President and CEO of scPharmaceuticals. “This Award recognizes Sensile as an Innovation Leader based on their accomplishments in developing transformative controlled drug delivery devices for use across a broad range of medical conditions.”

Important Information

scPharmaceuticals’ drug-device combination products are subject to FDA and other regulatory review and approval prior to commercial introduction and clinical use.

about scPharmaceuticals:

scPharmaceuticals, Inc. based in Lexington, MA, is a privately held pharmaceutical company developing a portfolio of transformative pharmaceutical products for subcutaneous delivery. Our innovative products are based on widely used generic drugs that currently require intravenous or intramuscular injections. They will be administered subcutaneously via the sc2Wear Pump. This avoids material risks and costs associated with the current delivery options. Our lead products are the first subcutaneous formulation of furosemide (the most widely used parenteral diuretic in treating heart failure), and ceftriaxone (the parenteral antibiotic most widely used outside the hospital setting). Our novel furosemide formulation enables convenient anytime anywhere use, for example in an outpatient setting instead of the emergency room or other in-patient settings. For ceftriaxone and other antibiotics, subcutaneous administration eliminates the need for PICCs (peripherally inserted central catheters), which are associated with serious complications, frequent adverse events and high medical costs. 

about Sensile Medical:

Sensile Medical based in Haegendorf, Switzerland, is a worldwide leader in Medical technology. It develops and manufactures high tech micro-pumps for dosing and delivery of a wide range of parenteral medications. The highly precise technology developed by Sensile Medical enables the safe and highly accurate delivery of drugs from very small to large doses. The company was founded in 2004. The company employs 60 people, primarily mechanical and electrical engineers, software developers, and microsystem mechanics. For further information, go to

Contact Information:

Katherine Taudvin
Director, Corporate Development
Telephone: (781) 301-6706